ArticlePharmacoEconomics2011
Standardizing the inclusion of indirect medical costs in economic evaluations.
Article in PharmacoEconomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review.PharmacoEconomics · 2023Pooled it
- Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.PharmacoEconomics · 2021Pooled it
- Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment.European journal of haematology · 2020Pooled it
- Evaluating the cost-effectiveness of adjuvanted influenza vaccine in the older adult population in the Netherlands.Human vaccines & immunotherapeutics · 2026Article
- A Health Literacy Intervention Targeting Chronic Kidney Disease Patients and Healthcare Professionals is Cost-saving: Findings from the Netherlands.Journal of general internal medicine · 2026Article
- Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Article
- Behavioral Responses to Healthcare Funding Decisions and Their Impact on Value for Money: Evidence From Australia.Health economics · 2025Article
- The impact of different perspectives on the cost-effectiveness of remote patient monitoring for patients with heart failure in different European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Article
- Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses.PharmacoEconomics · 2023Article
- Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses.PharmacoEconomics · 2023Article
- Cost-Effectiveness Analysis of MammaPrintPharmacoEconomics · 2023Article
- Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers.Applied health economics and health policy · 2022Article
- Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis.JMIR cardio · 2022Article
- Future Offspring Costs in Economic Evaluation.PharmacoEconomics · 2022Article
- Designing and testing of a health-economic Markov model to assess the cost-effectiveness of treatments for Bipolar disorder: TiBipoMod.Frontiers in psychiatry · 2022Article
- Incorporating future unrelated medical costs in cost-effectiveness analysis in China.BMJ global health · 2021Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A shortcoming of many economic evaluations is that they do not include all medical costs in life-years gained (also termed indirect medical costs). One of the reasons for this is the practical difficulties in the estimation of these costs. While some methods have been proposed to estimate indirect medical costs in a standardized manner, these methods fail to take into account that not all costs in life-years gained can be estimated in such a way. Costs in life-years gained caused by diseases related to the intervention are difficult to estimate in a standardized manner and should always be explicitly modelled. However, costs of all other (unrelated) diseases in life-years gained can be estimated in such a way. We propose a conceptual model of how to estimate costs of unrelated diseases in life-years gained in a standardized manner. Furthermore, we describe how we estimated the parameters of this conceptual model using various data sources and studies conducted in the Netherlands. Results of the estimates are embedded in a software package called 'Practical Application to Include future Disease costs' (PAID 1.0). PAID 1.0 is available as a Microsoft® Excel tool (available as Supplemental Digital Content via a link in this article) and enables researchers to 'switch off' those disease categories that were already included in their own analysis and to estimate future healthcare costs of all other diseases for incorporation in their economic evaluations. We assumed that total healthcare expenditure can be explained by age, sex and time to death, while the relationship between costs and these three variables differs per disease. To estimate values for age- and sex-specific per capita health expenditure per disease and healthcare provider stratified by time to death we used Dutch cost-of-illness (COI) data for the year 2005 as a backbone. The COI data consisted of age- and sex-specific per capita health expenditure uniquely attributed to 107 disease categories and eight healthcare provider categories. Since the Dutch COI figures do not distinguish between costs of those who die at a certain age (decedents) and those who survive that age (survivors), we decomposed average per capita expenditure into parts that are attributable to decedents and survivors, respectively, using other data sources.
Indexed as
Identifiers
21184618What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.